首页> 美国卫生研究院文献>Journal of Applied Clinical Medical Physics >Establishing radiation therapy treatment planning effects involving implantable pacemakers and implantable cardioverter‐defibrillators
【2h】

Establishing radiation therapy treatment planning effects involving implantable pacemakers and implantable cardioverter‐defibrillators

机译:建立涉及植入式起搏器和植入式心脏复律除颤器的放射治疗治疗计划效果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recent improvements to the functionality and stability of implantable pacemakers and cardioverter‐defibrillators involve changes that include efficient battery power consumption and radiation hardened electrical circuits. Manufacturers have also pursued MRI‐compatibility for these devices. While such newer models of pacemakers and cardioverter‐defibrillators are similar in construction to previously marketed devices – even for the recent MRI‐compatible designs currently in clinical trials – there is increased interest now with regard to radiation therapy dose effects when a device is near or directly in the field of radiation. Specifically, the limitation on dose to the device from therapeutic radiation beams is being investigated for a possible elevation in limiting dose above 200 cGy. We present here the first‐ever study that evaluates dosimetric effects from implantable pacemakers and implantable cardioverter‐defibrillators in high energy X‐ray beams from a medical accelerator. Treatment plan simulations were analyzed for four different pacemakers and five different implantable cardioverter‐defibrillators and intercompared with direct measurements from a miniature ionization chamber in water. All defibrillators exhibited the same results and all pacemakers were seen to display the same consequences, within only a a ± 1.8% deviation for all X‐ray energies studied. Attenuation, backscatter, and lateral scatter were determined to be −13.4%, 2.1% and 1.5% at 6 MV, and −6.1%, 3.1% and 5.1% at 18 MV for the defibrillator group. For the pacemaker group, this research showed results of −15.9%, 2.8% and 2.5% at 6 MV, and −9.4%, 3.4% and 5.7% at 18 MV, respectively. Limited results were discovered from scattering processes through computer modeling. Strong verification from measurements was concluded with respect to simulating attenuation characteristics. For IP and ICD leads, measured dose changes were less than 4%, existing as attenuation processes only, and invariant with regard to X‐ray energy.PACS number: 87.53.Bn, 87.53.Dq, 87.53.Tf, 87.66.Jj
机译:对植入式起搏器和心脏复律除颤器的功能和稳定性的最新改进涉及包括有效电池电量消耗和辐射硬化电路在内的变化。制造商还为这些设备寻求MRI兼容性。尽管这种较新的起搏器和心脏复律除颤器在结构上与以前销售的设备类似-即使对于目前正在临床试验中的最新MRI兼容设计-现在,当设备靠近或接近时,人们对放射疗法剂量效应的兴趣也越来越高直接在辐射领域。具体而言,正在研究治疗辐射束对设备剂量的限制,以提高200 cGy以上的限制剂量是否可能。我们在此提出的第一项研究评估了植入式起搏器和植入式心脏复律除颤器在医用加速器产生的高能X射线束中的剂量学效应。对四种不同的起搏器和五种不同的植入式心脏复律除颤器的治疗计划模拟进行了分析,并与水中微型电离室的直接测量结果进行了比较。所有除颤器均显示出相同的结果,并且所有起搏器均显示出相同的结果,所有研究的X射线能量的偏差仅在±1.8%之内。对于除颤器组,衰减,后向散射和横向散射在6 MV时确定为-13.4%,2.1%和1.5%,在18 MV时确定为-6.1%,3.1%和5.1%。对于起搏器组,这项研究表明,在6 MV时的结果分别为-15.9%,2.8%和2.5%,在18 MV时的结果分别为-9.4%,3.4%和5.7%。通过计算机建模从散射过程中发现的结果有限。在模拟衰减特性方面,得出了来自测量的有力验证。对于IP和ICD导线,测得的剂量变化小于4%,仅作为衰减过程存在,并且在X射线能量方面不变.PACS编号:87.53.Bn,87.53.Dq,87.53.Tf,87.66.Jj

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号